eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2023
vol. 40
 
Share:
Share:
Original paper

Non-multiple medium-sized congenital melanocytic nevi: to excise or to follow up?

Mateusz K. Mateuszczyk
1
,
Karolina Świerczyńska-Mróz
1
,
Iwona Chlebicka
1
,
Jacek C. Szepietowski
1

  1. Department of Dermatology, Venereology, and Allergology, Wroclaw Medical University, Wroclaw, Poland
Adv Dermatol Allergol 2023; XL (4): 561-566
Online publish date: 2023/06/18
Article file
- Non-multiple.pdf  [0.20 MB]
Get citation
 
 

Introduction

Congenital melanocytic nevi (CMN) are hamartomas, benign proliferative lesions composed of clonal proliferations of melanocytes, which occur during embryogenesis due to mutations. By definition, CMN are present at birth or begin to appear usually over the course of a few months of life [1, 2]. The names applied to congenital nevi reflect the largest estimated diameter of the nevus in adulthood: small (< 1.5 cm), medium (1.5–20 cm), large (> 20–40 cm), and giant (> 40 cm) [3]. The estimated incidence of CMN is as follows: small in 1 in 100 births, medium in 1 in 1000, large in 1 in 20,000, and giant in 1 in 500,000 [4]. Small and medium congenital melanocytic nevi are common lesions and generally remain benign throughout the lifetime of a person, and the risk of developing a melanoma is considered low [5]. Notwithstanding, the vast majority of studies focus on complications in large and giant CMN. There are a limited number of studies focused on the risk of melanoma in medium-sized congenital melanocytic nevi.

Aim

The aim of this article is to contribute to the expansion of knowledge in this area by publishing our analysis of surgically removed medium-sized CMN in the Unit of Dermatosurgery between 2016 and 2020. We conducted this study to optimize clinical care for patients with medium-sized CMN, by gathering more information due to the limited available data.

Material and methods

This retrospective study included 10 patients, who were operated on in the Unit of Dermatosurgery between 2016 and 2020. All participants presented with non-multiple medium-sized congenital melanocytic nevus. After dermatological examination, dermoscopy, and clinical evaluation, the decision about surgical excision was made. According to the location and size of the nevus, the technique of simple or serial excision was performed. The procedures were carried out after obtaining informed consent from the patients.

Results

In the study group there were 3 men and 7 women. The average age of the patients was 33 ±16.1 years. The diameter of the presented medium-sized congenital melanocytic nevi ranged 20–70 mm (mean: 36.4 ±18.1 mm). The area of the lesion ranged 11.31–100.53 cm2 with a mean size of 36.45 ±31.73 cm2. In most of the cases the reason for excision of the medium-sized CMN was evolution of the lesion or aesthetic considerations reported by the patient. However, bleeding, itch, or nodule development within the congenital melanocytic nevus were also observed. In 2 cases, due to the large size of the lesions, serial excisions were performed, while other CMN were removed surgically using a simple excision technique. Figure 1 shows a 2-step excision of a medium-sized CMN on the right thigh of a 68-year-old woman. The other case presents serial excision of a medium-sized CMN on the left forearm of a 26-year-old man (Figure 2). Possible malignant transformation to melanoma prompted the decision to perform excision along lymphatic drainage. Eight of ten medium-sized CMN were histologically described as benign, and 2 cases of malignant transformations were reported. The patient presenting with a 25-mm CMN located on the back, accompanied by bleeding and itching, was diagnosed with melanoma (Clark III, Breslow 0.8 mm) on the basis of histological examination (Figure 3). The second diagnosed melanoma (Clark I, Breslow 0.2 mm) arose on a 25-mm CMN on the trunk without any obvious clinical signs of malignancy other than evolution of the lesion reported by the patient. Table 1 summarizes the baseline characteristics of the patients.

Table 1

Cases of surgically removed medium-sized CMN in the Unit of Dermatosurgery in the years 2016–2020

No.AgeSexCMN locationMaximum clinical diameter [mm]Size [cm2]Reason for excisionHistological diagnosisType of operation
140MTrunk (back)2518.06Bleeding from the lesion, itchingMelanoma, Clark III, Breslow
0,8 mm
Simple
excision with
3 mm margin
268FRight thigh
(Figure 1)
7076.97Small tumour growing on the basis of the lesionCMN
(dermal nevus)
Two-step
excision
319FShank2011.31Itching, aesthetic reasonCMN
(dermal nevus)
Simple
excision
422FLeft buttock3020.73Evolution of the lesion according to the patientCMN
(dermal nevus)
Simple
excision
544MTrunk (back)
(Figure 3)
2515.71Evolution of the lesion according to the patientMelanoma, Clark I, Breslow 0.2 mmSimple
excision
626MLeft forearm
(Figure 2)
64100.53Evolution of the lesion according to the patient, aesthetic reasonCMN
(compound nevus)
Two-step
excision
718FRight arm5062.83Evolution of the lesion according to the patient,
aesthetic reason
CMN
(compound nevus)
Simple
excision
817FRight leg2514.14Evolution of the lesion according to the patient, aesthetic reasonCMNSimple
excision
934FLower back3020.73Evolution of the lesion according to the patient, aesthetic reasonCMN
(compound nevus)
Simple
excision
1042FAbdomen2516.49Evolution of the lesion according to the patientCMN
(compound nevus)
Simple
excision

[i] M – male, F – female, CMN – congenital melanocytic nevus.

Figure 1

Serial excision of medium-sized congenital melanocytic nevi (CMN) on the right thigh. A – Preoperative view, B – after the first excision, C – after the second excision

/f/fulltexts/PDIA/50865/PDIA-40-50865-g001_min.jpg
Figure 2

Serial excision of medium-sized congenital melanocytic nevi (CMN) on the left forearm. A – Preoperative view, B – preoperative marking before first stage, C – after the first excision

/f/fulltexts/PDIA/50865/PDIA-40-50865-g002_min.jpg
Figure 3

Malignant transformation of medium-sized congenital melanocytic nevi on the back to melanoma

/f/fulltexts/PDIA/50865/PDIA-40-50865-g003_min.jpg

Discussion

The risk of development of cutaneous melanomas within CMN is strongly associated with the size of the lesions. Cutaneous melanoma most likely arise on large and giant CMN [6]. For years malignant transformations of medium-sized CMN have been controversial [7].

It is worth noting that there is limited research evaluating such outcomes in the literature, and there is a need for increased knowledge on this topic. The most common location of medium-sized CMN is a lower limb [7]. However, the back is the most common site for CMN-associated melanomas [8]. There is no sex, ethnic group, or race predilection [9]. More than two-thirds of medium-sized CMN and a small subset of melanomas harbour somatic gain-of-function mutations in NRAS, which result in cellular proliferations and explain some pathways of cancerogenesis [10].

In 2010 Price et al. estimated the risk of small- and medium-sized CMN-associated melanomas to be less than 1% [10]. To emphasize the rarity of melanoma arising on small- and medium-sized CMN, scientists quote 3 substantial cohort studies of 680 people highlighting that no one was diagnosed with melanoma during a mean of 13.5 years of monitoring. One retrospective cohort study was based only on medium-sized CMN [10]. A total of 227 patients were monitored for a mean of 6.7 years, and no melanoma was reported. Two other cohort studies were retrospective and included all sizes of CMN. However, the authors divided CMN into groups on the basis of size. In the first study of 214 patients, no melanoma arose on 1–19 cm CMN during a mean 9.2 years of monitoring. The second research was based on 239 cases, and after a median follow-up time of 24 years no melanoma developed on 1–19 cm CMN [10]. In 2005 Zaal et al. [11] made a retrospective population-based study including 3929 patients with CMN, who were monitored for a mean of 4.7 years [11]. Eleven cases of malignant transformations were reported within ≤ 20 cm CMN, and no further detailed size-division was made [11]. In 2020 Caccavale et al. [8] analysed their collected data and performed retrospective research on all histologically confirmed melanomas over a 14-year period with the aim to evaluate the commonness of CMN-associated melanomas. In their database of 2159 melanomas 27 of them were associated with CMN (1.25%), and 5 of them with medium-sized CMN (0.23%). It is important to highlight that the most common CMN associated with melanoma turned out to be small (21; 0.97%) followed by medium-sized CMN [8]. Although malignant transformations occur more frequently within large and giant CMN, the incidence of small- and medium-sized CMN is much higher, which explains the foregoing results. In 2020 Cuevas et al. performed retrospective research to investigate melanoma predictors in dermoscopy. Their database consists of 119 skin tumours, 87 (73.1%) of which were histologically diagnosed as small- and medium-sized CMN and 32 (26.9%) as small- and medium-sized CMN-associated melanomas [12].

The true risk of malignant transformation of medium-sized CMN is nearly impossible to calculate with any degree of confidence. It could only be provided by long-lasting and large prospective research of untreated CMN. Furthermore, there are insufficient available data to assess an approximate estimate of the risk due to small study sizes, often a retrospective nature of the research, not considering medium-sized CMN, or combining small- and medium-sized CMN in one study group. However, according to available databases, the possibility of development of melanoma within medium-sized CMN is a fact, and considering the higher incidence of medium-sized CMN compared to large and giant CMN, we draw the conclusion that it can occur in a clinical setting.

Although malignant transformation of medium-sized CMN can occur, the magnitude of the risk remains unclear, and consistent recommendations for medical management do not exist. We do not routinely perform complete surgical removal as a prophylaxis against the development of melanoma. According to our clinical experience and knowledge, we recommend managing patients on an individual basis, taking into consideration multiple clinical attributes such as ease of monitoring, psychosocial complications, and aesthetic and functional concerns [3].

The presence of CMN may have an adverse impact on psychosocial well-being and can decrease quality of life [13, 14]. Therefore, the psychological impact of CMN should not be underestimated, and it can be a sufficient indication to perform surgery. In other cases, we recommend observation: regular visual inspection, baseline photographs, and dermoscopic follow-up.

Melanoma in solitary medium-sized CMN usually develops during or after puberty at the dermo-epidermal junction. On this account, dermoscopy is a crucial tool for follow-up and early melanoma detection [11, 15, 16]. Dermoscopy of congenital MN and acquired MN reveals similar features [17]. The dermoscopic pattern most likely to be visualized in medium-sized CMN is globular-reticular [18]. Macroscopically eccentric location of suspicious areas within CMN is an indicator of melanoma in small- and medium-sized CMN (333.3-fold increased risk) [12, 19]. In 2020 Cuevas et al. proposed dermoscopic predictors of melanoma arising in small- and medium-sized congenital nevi. Negative network (106.5-fold), grey angulated lines (12.5-fold), and atypical network (6.6-fold) were the dermoscopic features most associated with the development of melanoma [12].

However, well known factors that influence ease of monitoring with the naked eye and dermoscopy may influence the clinical approach: site of lesions, pigmentation, topography, thickness, hair presence, and non-cooperative patients [10].

Other clinical attributes such as CMN syndrome risk and extracutaneous melanoma risk are important in terms of management of CMN. Congenital melanocytic nevi syndrome is referred to as CMN associated with extracutaneous features, most commonly abnormalities in the central nervous system, i.e. neurocutaneous melanosis [20]. Risk factors for CMN syndrome include the presence of more than 2 medium-sized CMN. Children with CMN syndrome have significantly increased risk of extracutaneous and cutaneous melanoma associated with CMN size and abnormalities noted on screening MRI performed during the first years of life. Melanoma in the above-described subpopulation of patients is extremely aggressive with a high fatality rate [16]. Our research is based on solitary medium-sized CMN; therefore, the risk of malignant transformation within multiple medium-sized congenital melanocytic nevus will not be further discussed.

Tromberg et al. rightly pointed out that the main goal of CMN treatment is to avoid the development of melanoma while optimizing the aesthetic and functional outcomes [21].

Besides surgical excision, a wide range of treatment modalities such as dermabrasion, curettage, chemical peel, and laser treatments are available. However, all non-excisional techniques may be indisposed to early clinical diagnosis of melanoma. The surgical treatment methods included reconstructive ladder from direct excision with primary closure (single procedure or serial excision), skin grafting, expanded and unexpanded flap reconstruction, and free tissue transfer (in selective complex cases) [21].

The choice of procedure depends on the CMN size and the planned cosmetic effect. Moreover, some treatment modalities are more effective in different body regions. In a case of medium-sized congenital melanocytic nevus Yordanov et al. indicated local Dufourmentel skin flap as a reliable solution for surgical treatment of nevi located on the limbs [22]. Furthermore, staged excision has been favoured over single procedures for larger CMN. It is believed that multiple procedures give the skin a chance to stretch gradually, which possibly guarantees better outcomes [23]. Moreover, a retrospective review performed on 119 cases of small to medium congenital melanocytic nevi showed that treatment of small to medium CMN with excision followed by scar laser showed the highest IGA (Investigator’s Global Assessment) score, comparable to other treatment options. On the other hand, multiple surgical procedures may lead to the following complications: erythema, hypertrophic scarring, or widening of operation sites. Therefore, additional sessions with usage of a laser may provide more satisfaction for the patients [24]. It is also worth underlining that in the majority of cases a scar is socially more acceptable than a nevus [24, 25]. Summing up, for surgery of solitary, medium-sized CMN we utilize simple or staged total excision depending on the nevus size, to achieve the best cosmetic results and minimize scarring.

Conclusions

Malignant transformation of medium-sized CMN is a rare event, but in conjunction with an estimated incidence of medium-sized CMN of 1 in 1000 births, it can appear in clinical settings. Further studies in numerous samples are necessary to support any particular course of action for medium-sized CMN. In our opinion, long-lasting observation is the management of choice, and if there is need for surgery, we recommend total simple or staged excision depending on the nevus size.

Acknowledgments

This study was funded by a Research Grant (number: SUB.C260.21.011).

Conflict of interest

The authors declare no conflict of interest.

References

1 

Rhodes AR. Benign neoplasms and hyperplasias of melanocytes. In: Fitzpatrick TB (ed.). Dermatology in general medicine. 5th ed. McGraw-Hill. New York 1999; 1026-37.

2 

Rhodes AR, Albert LS, Weinstock MA. Congenital nevomelanocytic nevi: proportionate area expansion during infancy and early childhood. J Am Acad Dermatol 1996; 34: 51-62.

3 

Krengel S, Scope A, Dusza SW, et al. New recommendations for the categorization of cutaneous features of congenital melanocytic nevi. J Am Acad Dermatol 2013; 68: 441-51.

4 

Castilla EE, da Graça Dutra M, Orioli-Parreiras IM. Epidemiology of congenital pigmented naevi: I. Incidence rates and relative frequencies. Br J Dermatol 1981; 104: 307-15.

5 

Tannous ZS, Mihm MC Jr, Sober AJ, Duncan LM. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol 2005; 52: 197-203.

6 

DeDavid M, Orlow SJ, Provost N, et al. A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature. J Am Acad Dermatol 1997; 36 (3 Pt 1): 409-16.

7 

Sahin S, Levin L, Kopf AW, et al. Risk of melanoma in medium-sized congenital melanocytic nevi: a follow-up study. J Am Acad Dermatol 1998; 39: 428-33.

8 

Caccavale S, Calabrese G, Mattiello E, et al. Cutaneous melanoma arising in congenital melanocytic nevus: a retrospective observational study. Dermatology 2021; 237: 473-8.

9 

Cengiz FP, Emiroglu N, Ozkaya DB, et al. Dermoscopic features of small, medium, and large-sized congenital melanocytic nevi. Ann Dermatol 2017; 29: 26-32.

10 

Price HN, Schaffer JV. Congenital melanocytic nevi-when to worry and how to treat: facts and controversies. Clin Dermatol 2010; 28: 293-302.

11 

Zaal LH, Mooi WJ, Klip H, et al. Risk of malignant transformation of congenital melanocytic nevi: a retrospective nationwide study from The Netherlands. Plast Reconstr Surg 2005; 116: 1902-9.

12 

Cuevas RG, Villani A, Apalla Z, et al. Dermoscopic predictors of melanoma arising in small- and medium-sized congenital nevi. J Am Acad Dermatol 2021; 84: 1703-5.

13 

Bellier-Waast F, Perrot P, Duteille F, et al. Surgical treatment for giant congenital nevi: what are the psychosocial consequences for the child and family? Ann Chir Plast Esthet 2008; 53: 408-14.

14 

Koot HM, de Waard-van der Spek F, Peer CD, et al. Psychosocial sequelae in 29 children with giant congenital melanocytic naevi. Clin Exp Dermatol 2000; 25: 589-93.

15 

Schaffer JV. Update on melanocytic nevi in children. Clin Dermatol 2015; 33: 368-86.

16 

Kinsler VA, O’Hare P, Bulstrode N, et al. Melanoma in congenital melanocytic naevi. Br J Dermatol 2017; 176: 1131-43.

17 

Haliasos EC, Kerner M, Jaimes N, et al. Dermoscopy for the pediatric dermatologist part III: dermoscopy of melanocytic lesions. Pediatr Dermatol 2013; 30: 281-93.

18 

Stefanaki C, Soura E, Stergiopoulou A, et al. Clinical and dermoscopic characteristics of congenital melanocytic naevi. J Eur Acad Dermatol Venereol 2018; 32: 1674-80.

19 

Illig L, Weidner F, Hundeiker M, et al. Congenital nevi less than or equal to 10 cm as precursors to melanoma. 52 cases, a review, and a new conception. Arch Dermatol 1985; 121: 1274-81.

20 

Kinsler V, Shaw AC, Merks JH, Hennekam RC. The face in congenital melanocytic nevus syndrome. Am J Med Genet A 2012; 158A: 1014-9.

21 

Tromberg J, Bauer B, Benvenuto-Andrade C, Marghoob AA. Congenital melanocytic nevi needing treatment. Dermatol Ther 2005; 18: 136-50.

22 

Yordanov YP. Dufourmentel flap for surgical treatment of medium-sized congenital melanocytic nevi on the extremities. Dermatol Ther 2022; 35: e15357.

23 

Ibrahimi OA, Alikhan A, Eisen DB. Congenital melanocytic nevi: where are we now? Part II. Treatment options and approach to treatment. J Am Acad Dermatol 2012; 67: 515.e1-30.

24 

Lim JM, Oh Y, Lee SH, et al. Comparison of treatment options for small to medium congenital melanocytic nevi: a retrospective review of 119 cases. Lasers Surg Med 2019; 51: 62-7.

25 

Ceballos-Rodríguez MC, Redondo P, Tomás-Velázquez A, et al. Surgical outcomes and psychosocial impact of giant congenital melanocytic nevus surgery: a single-center case series of 136 patients. J Pediatr Surg 2021; 56: 2113-7.

Copyright: © 2023 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.